You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology

What Are the Key Inflammatory Processes in Patients with COPD?

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.
Klaus Rabe
MD, PhD, FERS
Klaus Rabe

Learning objectives

  • Understand the concept of different types of inflammation in chronic obstructive pulmonary disease (COPD) and recognize the significance of eosinophilic inflammation in COPD
  • Explore type 2 inflammation's role as a risk factor for disease instability and discuss targeted therapeutic strategies to improve care in COPD patients.
Tags
acute exacerbationsairflow limitationCOPDcytokinesdisease backgrounddisease controldisease progression
MAT-GLB-2404545 - 1.0 - 08/2024

About this expert

Pulmonology

Klaus Rabe

MD, PhD, FERS

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

See author’s profile
Klaus Rabe

Related resources

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?
Pulmonology
expert video

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?

GINA Asthma Decision Tree
Pulmonology
videoanimation

GINA Asthma Decision Tree

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters
Pulmonology
expert video

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

Asthma White Board Video
Pulmonology
videoanimation

Asthma White Board Video

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?
Pulmonology
expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Pulmonology
interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?
Pulmonology
Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

On-Treatment Asthma Remission: Moving Beyond Control
Pulmonology
interactivity

On-Treatment Asthma Remission: Moving Beyond Control

What Are the Key Inflammatory Processes in Patients with COPD?
Pulmonology
expert video

What Are the Key Inflammatory Processes in Patients with COPD?

Clinical Remission as a Goal in Asthma Clinical Practice
Pulmonology
expert video

Clinical Remission as a Goal in Asthma Clinical Practice

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
expert video

FeNO as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma
Pulmonology
expert video

IgE as a Biomarker for Type 2 Asthma

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management
Pulmonology
interactivity

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Pediatric Asthma Patient Case Tool: Ash
Pulmonology
interactivity

Pediatric Asthma Patient Case Tool: Ash

The Cycle of Inflammation in Adult Asthma
Pulmonology
interactivity

The Cycle of Inflammation in Adult Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients
Pulmonology
expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

What is the Role of FeNO as an Asthma Biomarker?
Pulmonology
expert video

What is the Role of FeNO as an Asthma Biomarker?

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients
Pulmonology
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD
Pulmonology
expert video

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

Why Is It Important to Assess Lung Function in Pediatric Asthma
Pulmonology
interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline
Pulmonology
videoanimation

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

ERS 2024 | IL-33 A Promising Target
Pulmonology
expert video

ERS 2024 | IL-33 A Promising Target

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling
Pulmonology
expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

Clinical Manifestations Associated With Airway Remodeling in Asthma
Type 2 Inflammation
expert video

Clinical Manifestations Associated With Airway Remodeling in Asthma

Impact of Exacerbations in COPD
Type 2 Inflammation
expert video

Impact of Exacerbations in COPD

Role of Type 2 Cytokines in Asthma and COPD
Type 2 Inflammation
expert video

Role of Type 2 Cytokines in Asthma and COPD

Exacerbations Lead to Worsening Lung Function
Type 2 Inflammation
expert video

Exacerbations Lead to Worsening Lung Function

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region